Emerging evidence shows that poor metabolic health can impact drug efficacy, highlighting the need for integrated approaches in drug development and dietary guidelines. A recent study reveals that late eating patterns are associated with increased metabolic syndrome risk, which could complicate treatment responses to therapies. Concurrently, India’s move towards centralized licensing for sterile drugs aims to enhance quality control in the pharmaceutical sector, ensuring that medications are both effective and safe. By addressing metabolic health through dietary patterns and improving drug manufacturing standards, the biopharma industry can better navigate the complexities of patient care in an era where lifestyle factors increasingly influence treatment outcomes.
